10x Genomics (TXG) announced that it has signed a definitive agreement to acquire Scale Biosciences, a company in innovative and scalable single cell analysis. The acquisition provides 10x with key inventions and technologies that will advance innovation across the company’s Chromium platform. It also helps broaden access to single cell analysis by making it more powerful, affordable, and accessible to researchers worldwide.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10x Genomics reports Q2 EPS 28c vs (32c) last year
- 10x Genomics sees Q3 revenue $140M-$144M, consensus $144.53M
- 10x Genomics: Strategic Positioning and Growth Potential Justify Buy Rating
- 10x Genomics price target raised to $13 from $12 at BofA
- 10x Genomics price target raised to $13 from $12 at Barclays